BIVI BioVie Inc. Class A

BioVie, Inc. is a development stage biopharmaceutical company, which discovers, develops, and commercializes drug therapies for liver disease. It focuses on BIV201 which treats ascites due to chronic liver cirrhosis. The company was founded on April 10, 2013 and is headquartered in Santa Monica, CA.

$25.81  +1.32 (5.39%)
As of 03/02/2021 15:58:00 EST     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Small cap
Health Care
Biotechnology
USA

05/05/2014
13,916,164
103,624
$340,806,856
0.00%
SEC Edgar Online
10-Q
10-K



Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
0.00
25.68
0.00
-116.59%
0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy